Our focus in human health includes infectious diseases, where we are developing a vaccine for COVID-19, as well as an anti-fibrotic therapeutic candidate, IBIO-100, for idiopathic pulmonary fibrosis, amongst other indications. Some studies1 have shown that a number of patients recovering from COVID-19 have severe pulmonary fibrosis sequela.
Oncology is another focus, particularly in areas of high unmet medical need. We’re developing immunotherapy, IBIO-101, which has shown strong anti-tumor responses in preclinical models of disease. We expect our oncology pipeline to continue to grow with the in-house discovery capabilities established in San Diego in mid 2021, as well as with our partnership with RubrYc for access to their AI-enabled antibody design technologies.
In the field of animal health, we’re developing a vaccine candidate, IBIO-400, for classical swine fever – a contagious, often fatal disease affecting both feral and domesticated pigs.
